Fennec Pharmaceuticals Inc.
HealthcareNASDAQ:FENC · NASDAQ Capital Market
+$0.15 today
Vol 0.25M · Avg 0.26M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-27.8%
avg 44.3%
ROIC
-10.7%
avg -84.2%
ROA
-13.9%
avg -53.9%
Analysis
ROIC is currently the strongest return metric at -10.7% versus its period average of -84.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jeffrey S. Hackman | Chief Executive Officer & Director | $632,176.00 | — | 63 | $62,825.00 | 0.22% |
Robert C. Andrade | Chief Financial Officer | $552,646.00 | — | 51 | $289,269.00 | 1.01% |
Pierre S. Sayad | Chief Medical Officer | $464,081.00 | — | — | $21,015.00 | 0.07% |
Lei Fang | President of Pharstat Inc | — | — | — | — | — |
Mark Gowland | Controller | — | — | — | — | — |
Terry Evans | Chief Commercial Officer | — | — | — | $21,015.00 | 0.07% |
Christiana Cioffi | Chief Strategy Officer | — | — | — | $24,176.00 | 0.08% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
22
$11.41M
Net Sentiment
$11.41M
Net selling
Most Active
Raykov Rosty
12 transactions
1–10 of 22
Analysis
Insiders reported 0 buys worth $0.00 and 22 sells worth $11.41M over the last 12 months. That adds up to net selling of $11.41M. Raykov Rosty was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$279.42M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
$100.28M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
Who manages FENC?
Fennec Pharmaceuticals Inc. (FENC) lists 7 active executives. The top listed executive is Pierre S. Sayad, Chief Medical Officer.
Are FENC insiders buying or selling?
Recent insider activity shows net selling of $3.25M.
Explore More
Continue the stock analysis
Jump to another research area for this company.